Nitza Thomasson-Perret
Directeur/Membre du Conseil chez NH THERAGUIX SAS
Profil
Nitza Thomasson-Perret is the founder of Brainever SAS, which was founded in 2015.
She is currently the Chairman at Ntz Consulting SASU, Director at NH TherAguix SAS, and Director at BrainTale SAS.
Her former positions include Director-Preclinical Department at Sanofi, Head-Biological Studies Neurospychiatry Department at Les Laboratoires Servier SAS, Head-Early Drug Development at Fovea Pharmaceuticals SA, and Head-Preclinical Development at Gensight Biologics SA from 2013 to 2015.
She was also the Head-Development at Tissium SA.
Postes actifs de Nitza Thomasson-Perret
| Sociétés | Poste | Début |
|---|---|---|
| NH THERAGUIX SAS | Directeur/Membre du Conseil | 22/02/2019 |
BrainTale SAS
 BrainTale SAS Packaged SoftwareTechnology Services BrainTale SAS engages in the development and distribution of diagnosis and prognosis tools for brain injured patients. Its products include BrainQuant and BrainScore-coma. The company was founded by Vincent Perlbarg, Julie Rachline, Didier Cassereau, Louis Puybasset, Damien Galanaud, and Lionel Velly on July 6, 2018 and is headquartered in Paris, France. | Directeur/Membre du Conseil | 03/06/2021 |
| Ntz Consulting SASU | Président | - |
Anciens postes connus de Nitza Thomasson-Perret
| Sociétés | Poste | Fin |
|---|---|---|
Brainever SAS
 Brainever SAS Pharmaceuticals: MajorHealth Technology Brainever SAS manufactures pharmaceutical products. It develops medicines for nervous system diseases. The company was founded on March 31, 2015 and is headquartered in Paris, France. | Fondateur | - |
Tissium SA
 Tissium SA BiotechnologyHealth Technology Tissium SA engages in the development and commercialization of biodegradable sealants and adhesives for invasive surgery. It offers biomimetic wound closure solutions. The company was founded by Bernard J. Gilly, Robert S. Langer, Christophe Bancel, Jeff Karp, Jacques Marescaux, Maria Pereira, and Patrick Houvet in 2013 and is headquartered in Paris, France. | Corporate Officer/Principal | - |
| SANOFI | Corporate Officer/Principal | - |
Fovea Pharmaceuticals SA
 Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Corporate Officer/Principal | - |
Les Laboratoires Servier SAS
 Les Laboratoires Servier SAS Pharmaceuticals: MajorHealth Technology Les Laboratoires Servier SAS manufactures medicines for the treatment of diabetes, venous disease, and cancer. It also offers pharmaceutical products for cardiovascular illnesses such as hypertension, heart failure, and stroke. The company was founded by Jacques Servier in 1954 and is headquartered in Suresnes, France. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SANOFI | Health Technology |
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Les Laboratoires Servier SAS
Les Laboratoires Servier SAS Pharmaceuticals: MajorHealth Technology Les Laboratoires Servier SAS manufactures medicines for the treatment of diabetes, venous disease, and cancer. It also offers pharmaceutical products for cardiovascular illnesses such as hypertension, heart failure, and stroke. The company was founded by Jacques Servier in 1954 and is headquartered in Suresnes, France. | Health Technology |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Health Technology |
Tissium SA
Tissium SA BiotechnologyHealth Technology Tissium SA engages in the development and commercialization of biodegradable sealants and adhesives for invasive surgery. It offers biomimetic wound closure solutions. The company was founded by Bernard J. Gilly, Robert S. Langer, Christophe Bancel, Jeff Karp, Jacques Marescaux, Maria Pereira, and Patrick Houvet in 2013 and is headquartered in Paris, France. | Health Technology |
Brainever SAS
Brainever SAS Pharmaceuticals: MajorHealth Technology Brainever SAS manufactures pharmaceutical products. It develops medicines for nervous system diseases. The company was founded on March 31, 2015 and is headquartered in Paris, France. | Health Technology |
NH TherAguix SAS
 NH TherAguix SAS Pharmaceuticals: MajorHealth Technology NH TherAguix SAS operates as a biotechnology company. The firm develops a nanodrug against cancer called AGuIX based on nanometric structuring that allows intravenous injection and the combination of the following properties to fight tumors: targeting, imaging, and treating. The company was founded by G?raldine Le Duc, Olivier Tillement and Fran?ois Lux in on December 11, 2015 and is headquartered in Meylan, France. | Health Technology |
BrainTale SAS
BrainTale SAS Packaged SoftwareTechnology Services BrainTale SAS engages in the development and distribution of diagnosis and prognosis tools for brain injured patients. Its products include BrainQuant and BrainScore-coma. The company was founded by Vincent Perlbarg, Julie Rachline, Didier Cassereau, Louis Puybasset, Damien Galanaud, and Lionel Velly on July 6, 2018 and is headquartered in Paris, France. | Technology Services |
| Ntz Consulting SASU |
